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The management of ovarian cancer presents many problems
for the clinician. In particular if a patient is not cured by
primary surgery then the ultimate outcome is likely to be
very poor. Although patients respond to first line treatment
in the form of chemotherapy and possibly radiotherapy the
role of second line treatment of ovarian cancer is less well
defined. The purpose of this Workshop was to discuss the
potential role of second line treatment in ovarian cancer, to
identify which patients might most benefit from such treat-
ment, to review the current agents available and to discuss
potential future agents. Finally there was a report on the
assessment and optimising of quality of life of patients
suffering from recurrent ovarian cancer.
Selecting patients for treatment
Since a majority of patients will respond to established
chemotherapy agents, it is difficult ethically to evaluate new
agents as first line treatment. Evaluation of new agents is
therefore confined to patients relapsing or progressing at the
end of primary treatment. In the many studies that have
been carried out evaluating a wide range of chemothera-
peutic agents, widely varying results have been seen. Such
wide variations have important implications for the evalu-
ation of new drugs and suggest that factors other than
chemotherapeutic activity influence response.
Mr C.W.E. Redman (Birmingham) reported the findings
of a study performed to identify factors that might influence
response and which, in turn, may be used to predict the
likelihood of response to chemotherapy. This study com-
prised a retrospective analysis of patients treated in a
number of phase II studies by the West Midlands Ovarian
Cancer Group over a period of three years. A total of 92
patients had been entered into five studies evaluating regi-
mens that had been chosen on the basis of in vitro cyto-
toxicity and single agent phase II data. Using univariate and
subsequent stepwise discriminant analysis, three independent
predictive variables were defined: interval from the end of
prior therapy to commencing the phase II treatment, FIGO
stage at initial presentation and the largest diameter of the
residual disease after primary surgery. The interval from the
end of prior treatment was the single most important
predictive factor. A classification function was derived from
the discriminant analysis that correctly predicted outcome in
88% of patients (71% of responders and 97% of non-
responders). The robustness of this model was tested by
random testing of subsets of the study population. The
observations of this study have implications for the design of
new phase II studies and also for the clinical management of
patients relapsing after primary therapy.
The role of chemotherapy
The aim of second line treatment needs to be defined,
whether it is to achieve a 'response' according to UICC
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criteria, to stabilise disease, provide symptom relief, increase
survival or improve the quality of life. Dr Rankin (Glasgow)
addressed this problem with particular reference to the
timing of cisplatinum or platinum analogues.
The majority of patients responding to first line treatments
will relapse. Patients who fail initial treatment with
alkylating agents may respond to second-line cisplatin.
However the majority of patients receive first-line cisplatin.
The timing of cisplatin therapy in a prospective manner has
been addressed in two prospective studies. In a large
Australian study, 369 patients were randomised to receive
either chlorambucil and cisplatin as first line treatment or
chlorambucil alone with the combination at relapse. The
time to overall treatment failure was not significantly
different. Similarly in a British study, 89 patients were
randomised to either a platinum combination regimen or
first line chlorambucil with the combination at relapse.
While the initial response was higher in the combination
arm, the median survival was not significantly different.
Dr W. ten Bokkel Huinink (Amsterdam) reviewed the role
of very high dose cisplatinum therapy at relapse and also the
potential role of intraperitoneal therapy. While responses are
seen in patients refractory to cisplatinum using high dose
cisplatinum, these are of short duration and associated with
an increase in both nephro- and neurotoxicity. These may be
ameliorated to some extent by protective agents such as
hypertonic saline and thiosulphate but such approaches
should be regarded as evaluating agents for first line therapy,
rather than definitive treatment at relapse.
Intraperitoneal therapy has also shown encouraging results
in terms of response rates, but again these are short-lived
unless complete remission is obtained. This is usually only
seen in patients with minimal residual disease after primary
treatment. The potential of intraperitoneal therapy is unlik-
ely to be realised until it is studied in protocols which use
this approach as part of primary treatment.
Patients who fail to respond to, or who relapse after,
platinum therapy have a median survival of only six months.
Second-line therapy is given at symptomatic relapse to
relieve the often protracted and distressing symptoms and
ideally requires to be effective yet relatively non-toxic.
Undoubtedly some patients do derive meaningful palliation
though in the main, results are disappointing.
An overall assessment of the value of second-line treat-
ment is difficult to evaluate on the basis of current studies. It
is becoming increasingly apparent that certain patients are
unlikely to derive any benefit from second-line chemo-
*therapy, particularly those who fail to response to cisplatin
therapy or who relapse soon afterwards and to some extent
this may mask the benefit of second-line therapy. Thus
response rates observed in phase II trials of second-line
regimens may be more a reflection of the patients' tumour
characteristics than the activity of the drugs in question. For
example, cisplatin and etoposide given after first-line cis-
platin have response rates ranging from 9 to 53%. The
marked difference in response rates between trials illustrates
the need for commonly agreed entry criteria and accurate
description of the patient characteristics. To evaluate second-
line chemotherapy adequately the following patient infor-
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mation is required: stage at presentation, histology and
tumour grade, details of first-line therapy and cumulative
doses, progression-free interval, age, performance status and
volume of disease at the start of salvage therapy. In addition
there should be adequate numbers of patients to give narrow
confidence limits.
At present, in the absence of any new significant thera-
peutic advance, attention must be focused on how to achieve
useful palliation in patients likely to respond with the least
associated toxicity.
Hormonal treatment
The normal ovary is a hormone dependent organ and
progestogen receptors have been found in ovarian cancer.
The potential for hormonal manipulation of ovarian cancer
therefore exists. Dr Quinn (Melbourne) reviewed the current
use of hormonal therapy in ovarian cancer. Progestogen
therapy has been used in patients with advanced ovarian
cancer since 1960, since when a total of 317 patients have
been reported with an 18% overall response rate. Anti-
oestrogens have been used in 295 patients since 1981 with a
14% overall response rate. The reported response rates for
these agents have varied between 0 and 66% probably due
to patient selection since the vast majority have been heavily
pre-treated, some have started therapy when bowel obstruc-
tion has been present and in most series no comment has
been made on tumour grade, ploidy, receptor status or
perhaps most importantly, response to previous therapy.
Dr Slevin (London) reported on the studies of Tamoxiten
carried out by the London gynaecological oncology group.
These were very disappointing with only one partial
remission in over 80 patients. Even when a loading dose of
Tamoxifen was used there was no improvement. A number
of patients with static disease have been seen and this raises
the question of whether the disease in some patients could be
held under control using hormonal manipulation. Patients
left with bulky disease especially if they had a poor perfor-
mance status have a dismal prognosis and in view of the
relative lack of toxicity of hormonal manipulation a case
could be made for investigating its efficacy as primary
therapy in these circumstances. It would be necessary to
evaluate such treatment in a randomised way, comparing
conventional non-toxic therapy such as single oral alkylating
agent therapy with hormonal manipulation. A population of
patients with ovarian cancer who are frail and who have
extensive disease exist who would be appropriate for such an
approach.
It is not yet established which might be the most appro-
priate hormone manipulation agent. A variety of
progestogenic agents have been used given by a variety of
routes and doses. The choice ofprogestogen should take into
account progestational effects in vitro, receptor binding
characteristics when these are available and pharmacokinetic
information.
Biological response modifiers
There has been increasing interest in the potential role of
biological response modifiers in a number of malignancies.
BRMs may have a cytostatic or cytotoxic effect on a cancer
either directly or by affecting the host response to the
tumour. There is some evidence that their primary mode of
action may be influenced by their concentration at the
micro-environmental level around the malignant cell.
Ovarian cancer presents an interesting model for the action
of biological response of BRMs since it is confined to the
peritoneal cavity until very late stages. Potentially this means
that high concentrations of BRMs can be achieved intra-
peritoneally. The peritoneal cavity also contains a wide range
of immuno-competent cells including macrophages, natural
killer (NK) cells and T- and B-lymphocytes. Initial studies of
x2-interferon given systemically were disappointing with no
responses in previously treated patients with cisplatinum.
However, when 2-interferon was given intraperitoneally
high levels were achieved locally and substantial plasma
levels were sustained for 6 days. Ascites was reduced in four
out of seven patients associated with elevated NK cell
activity in peritoneal fluid. In another phase II trial from
UCLA of 14 patients, there were four complete remissions
and one partial remission in patients who had presented with
microscopic (cytologically positive) disease at second look.
No patient with >5mm disease bulk responded. There is
some data to suggest that interferon gamma may show some
activity and recent studies in vitro have suggested that a
combination of BRMs may be able to cure ovarian cancer in
some animal models. This has yet to be substantiated in a
clinical setting.
Work on growth factors relating to ovarian cancer is not
very advanced but a crude product called Mullerian inhibi-
ting substance has been obtained and affects the growth of
ovarian cancer cell lines.
The data available for BRMs as active agents in ovarian
cancer are disappointing at the present time. They may have
a potential role in association with conventional cytotoxic
agents or in combination with other cytokines. These possi-
bilities remain speculative, however.
Control of toxicity and quality of life
While relapsed ovarian cancer may be a useful test bed for
the evaluation for new agents, treatment in this setting is
primarily palliative and therefore the control of toxicity and
the quality of life of the patients is critical. Dr Soukop
(Glasgow) reviewed the control of nausea and vomiting. This
still remains a major problem in cancer chemotherapy. The
current anti-emetics, including dexamethasone, high dose
metoclopramide and lorazepam, may be effective in produc-
ing major control of vomiting in up to two-thirds of
patients. One-third of patients still experience significant
problems. A number of compounds which are 5HT3 antago-
nists have now been produced and these appear to be
effective anti-emetic agents, given control in some cases of
cis-platinum-induced vomiting where conventional anti-
emetic therapy has failed. Their incorporation into estab-
lished regimens has not yet been achieved and currently no
standard regimen is ideal for all patients, especially those
receiving cis-platinum. The best regimes include high dose
metoclopramide given by a loading dose followed by i.v.
infusion probably in combination with dexamethasone.
Nabilone, prochlorperazine and dexamethasone may be a
useful regime especially in young patients. On failure of such
anti-emetic regimens the early use of lorazepam alone or in
combination may provide a useful amnesic effect, helping to
prevent anticipatory nausea and vomiting.
The maintenance and assessment of quality of life of
patients during therapy for cancer is an important goal.
There are myriad influences on the quality of life in all of us
and numerous methods of assessment and measurement
exist. No single technique has yet been established as ideal
but the gate theory proposed by Dr S. Bindermann suggests
that unless the multi-factorial influences upon the patients'
lives engender in them some expression of anxiety or
depression, they are unlikely to be adversely affecting the
quality of their lives. Since scales now exist for the measure-
ment of anxiety and depression these may be the most
appropriate methods at the present time for assessing quality
of life. Attention to such assessment routinely in chemo-
therapy trials is now necessary especially in the palliative
setting of advanced ovarian cancer.GYNAECOLOGICAL CANCER WORKSHOP 659
Summary
The workshop demonstrated that progress remains slow in
improving the outcome for women with advanced ovarian
cancer. While recurrent ovarian cancer responds to a wide
variety of agents, it is difficult to envisage incorporating
most of these agents into primary treatment regimens. In the
routine management of patients requiring second line treat-
ment, the emphasis should be on symptom relief and quality
of life, while those patients suitable for evaluation of new
agents should be carefully selected to ensure that 'no hopers'
were not included in phase II studies.